From Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines to Current Clinical Practice
Tóm tắt
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines have been promulgated to improve the management of chronic obstructive pulmonary disorder (COPD). To evaluate the extent to which the current therapeutic approach to COPD conforms to GOLD guidelines. This was a multicentre observational study of elderly COPD patients enrolled for acute care in general medicine or geriatric wards in tertiary hospitals in Italy in April 2002. Our series consisted of 471 patients >64 years of age consecutively admitted for acute exacerbations of COPD to wards participating in the study. Data describing drugs used prior to exacerbation and prescribed at discharge were collected using a standardised protocol. Changes in prescription at discharge were then compared with home therapy. Demographic variables and indices of COPD severity and co-morbidity were tested as potential correlates for the main outcome measure ‘variant prescription’, i.e. prescription of a drug considered as a third-line treatment (e.g. methylxanthines) or not recommended (e.g. mucolytics) by GOLD guidelines. The correlation was assessed first by univariate analysis and then by logistic regression analysis. At discharge, prescription of short-acting β2-adrenoceptor agonists had decreased from 26.3% to 14.0%. Conversely, increases in prescription of long-acting β2-adrenoceptor agonists (from 43.1% to 68.4%), inhaled corticosteroids (50.7% to 69.6%) and anticholinergics (17.2% to 22.3%) were seen. The rate of use of methylxanthines was 49.7% before admission and 44.8% at discharge, with previous use being the main correlate of discharge prescription for this class of drugs (odds ratio [OR] = 4.35; 95% CI 2.88, 6.54). The rate of use of mucolytics was 26.3% before admission and 26.8% at discharge, with use of mucolytics prior to admission being the only correlate of discharge prescription (OR = 4.10; 95% CI 2.47, 6.82). Hospitalisation resulted in increased adherence to GOLD guidelines in patients with COPD, but the rate of use of anticholinergics was distinctly low and that of methylxanthines and mucolytics surprisingly high. A carry-over effect (i.e. of therapy prescribed by general practitioners on that prescribed by hospital-based physicians) likely accounts for most of the ‘variant prescriptions’ seen at discharge from the acute care hospital.
Tài liệu tham khảo
Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163(5): 1256–76
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2005 [online]. Available from URL: http://www.goldcopd.com/download.asp?.intId=231 [Accessed 2006 Feb 6]
Teramoto S, Fukuchi Y. Improvements in exercise capacity and dyspnoea by inhaled anticholinergic drug in elderly patients with chronic obstructive pulmonary disease. Age Ageing 1995; 24(4): 278–82
Adcock IM, Maneechotesuwan K, Usmani O. Molecular interactions between glucocorticoids and long-acting beta2-agonists. J Allergy Clin Immunol 2002; 110: S261–8
Allen SC. Competence thresholds for the use of inhalers in people with dementia. Age Ageing 1997; 26(2): 83–6
Murciano D, Auclair MH, Pariente R, et al. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320: 1521–5
Asia Pacific COPD Roundtable Group. Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective. Respirology. 2005 Jan; 10(1): 9–17
Tan WC. The Global Initiative for Chronic Obstructive Lung Disease: gold standards and the Asia-Pacific perspective. Respirology 2002; 7(1): 1–2
Decramer M, Bartsch P, Pauwels R, et al. Management of COPD according to guidelines: a national survey among Belgian physicians. Monaldi Arch Chest Dis 2003; 59(1): 62–80
Rutschmann OT, Janssens JP, Vermeulen B, et al. Knowledge of guidelines for the management of COPD: a survey of primary care physicians. Respir Med 2004; 98(10): 932–7
Antonelli Incalzi R, Corsonello A, Pedone C, et al. Use of antibiotics in elderly patients with exacerbated COPD: the OLD-COPD study. J Am Geriatr Soc 2006; 54: 642–7
American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: s77–s120
Conwell Y, Forbes NT, Cox C, et al. Validation of a measure of physical illness burden at autopsy: the Cumulative Illness Rating Scale. J Am Geriatr Soc 1993; 41: 38–41
Di Iorio A, Longo AL, Mitidieri Costanza A, et al. Characteristics of geriatric patients related to early and late readmissions to hospital. Aging Clin Exp Res 1998; 10: 339–46
Jones PW, Quirk FH, Bavestock CM, et al. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis 1992; 145: 1321–7
Carone M, Bertolotti G, Anchisi F, et al. Il St. George’s Respiratory Questionnaire (SGRQ): la versione italiana. Rass Pat App Respir 1999; 14: 31–7
Carosella L, Pahor M, Pedone C, et al. Pharmacosurveillance in hospitalized patients in Italy. Study design of the ‘Gruppo Italiano di Farmacovigilanza nell’Anziano’ (GIFA). Pharmacol Res 1999; 40: 287–95
Pahor M, Chrischilles EA, Guralnik JM, et al. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 1994; 10: 405–11
Ovbiagele B, Hills NK, Saver JL, et al. Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA. Neurology 2006; 66: 313–8
Winkelmayer WC, Fischer MA, Schneeweiss S, et al. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis 2005; 46: 1080–7
Heffner JE, Ellis R. The guideline approach to chronic obstructive pulmonary disease: how effective? Respir Care 2003; 48: 1257–66
Lomas J, Anderson GM, Dominick-Pierre K, et al. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med 1989; 321: 1306–11
Linee guida GOLD: progetto mondiale broncopneumopata cronica ostrutiva (BPCO) [online]. Available from URL: http://www.goldcopd.it [Accessed 2006 May 14]
Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993; 342: 1317–22
Bero LA, Grilli R, Grimshaw JM, et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ 1998; 317: 465–8
Ramsey SD. Suboptimal medical therapy in COPD: exploring the causes and consequences. Chest 2000; 117 (2 Suppl.): 33S–7S
Miravitlles M, Mayordomo C, Artes M, et al. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitacion Obstructiva al Flujo a Ereo. Respir Med 1999; 93: 173–9
Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 2005; 97: 125–34
Jones V, Fernandez C, Diggory P. A comparison of large volume spacer, breath-activated and dry powder inhalers in older people. Age Ageing 1999; 28(5): 481–4
Rogers DF. Mucoactive drugs for asthma and COPD: any place in therapy? Expert Opin Investig Drugs 2002; 11(1): 15–35
Dekhuijzen PNR. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J. 2004; 23(4): 629–36
Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001; 322(7297): 1271–4
Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365(9470): 1552–60
Malerba M, Ponticiello A, Radaeli A, et al. Effect of twelvemonths therapy with oral ambroxol in preventing exacerbations in patients with COPD: double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther 2004; 17: 27–34
Barros MJ, Rees PJ. Bronchodilator responses to salbutamol followed by ipratropium bromide in partially reversible airflow obstruction. Respir Med 1990; 84(5): 371–5
Hasani A, Toms N, Agnew JE, et al. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004; 125: 1726–34
Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123: 1441–9
Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143: 317–26
Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19(2): 217–24
Urbano FL, Pascual RM. Contemporary issues in the care of patients with chronic obstructive pulmonary disease. J Manag Care Pharm 2005; 11 (5 Suppl. A): S2–13
Pelletier-Fleury N, Lanoe JL, Fleury B, et al. The cost of treating COPD patients with long-term oxygen therapy in a French population. Chest 1996; 110: 411–6
Miravitlles M, Murio C, Guerrero T, et al. Treatment of chronic bronchitis and chronic pulmonary obstructive disease in primary care. Arch Bronconeumol 1999; 35: 173–8